BackEyePoint Pharmaceuticals Overview

EyePoint Pharmaceuticals Total Liabilities

Track EyePoint Pharmaceuticals's total liabilities ($58M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$57.74M
10.01% YoYΔ $-6.42M vs prior year quarter

Peer average

Loading

EyePoint Pharmaceuticals Total Liabilities History

Loading

EyePoint Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

EyePoint Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

EyePoint Pharmaceuticals (EYPT) FAQ

The latest total liabilities for EYPT is $58M as of March 2026. That compares with $64M in the prior-year period — down 10.0% year over year. Investors often review this figure alongside EyePoint Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EYPT's total liabilities moved from $64M to $58M — a 10.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in EyePoint Pharmaceuticals's operating scale or balance-sheet position.

A total liabilities figure of $58M for EYPT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EYPT's total liabilities ($58M), review year-over-year change from $64M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack EyePoint Pharmaceuticals's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.